Epigenetic–smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early‐stage NSCLC patients
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12785
Abstract: Tripartite motif containing 27 (TRIM27) is highly expressed in lung cancer, including non‐small‐cell lung cancer (NSCLC). Here, we profiled DNA methylation of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tumours from 613 early‐stage… read more here.
Keywords: methylation; nsclc patients; early stage; overall survival ... See more keywords
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13267
Abstract: Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard‐of‐care treatment, even though only approximately 5.8% of patients will benefit. Identifying patients with minimal residual disease (MRD) after surgery using… read more here.
Keywords: nsclc patients; stage iiia; detection; length analysis ... See more keywords
SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1545
Abstract: Lymph node metastasis is an important prognosis factor in non‐small cell lung cancer (NSCLC) patients. The aim of this study was to investigate the role of epithelial to mesenchymal transition (EMT) in lymph node progression… read more here.
Keywords: lymph node; nsclc patients; progression early; node progression ... See more keywords
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04625-9
Abstract: Immunotherapy has improved outcomes for patients with non-small cell lung cancer (NSCLC), yet durable clinical benefit (DCB) is experienced in only a fraction of patients. Here, we test the hypothesis that radiomics features from baseline… read more here.
Keywords: clinical benefit; pet; immunotherapy; nsclc patients ... See more keywords
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02506-x
Abstract: A minority of NSCLC patients benefit from anti-PD1 immune checkpoint inhibitors. A rational combination of biomarkers is needed. The objective was to determine the predictive value of tumor mutational load (TML), CD8+ T cell infiltration,… read more here.
Keywords: cd8; class; nsclc patients; hla class ... See more keywords
Quality assessment using EQ-5D-5L after lung surgery for non-small cell lung cancer (NSCLC) patients
Sign Up to like & getrecommendations! Published in 2019 at "General Thoracic and Cardiovascular Surgery"
DOI: 10.1007/s11748-019-01136-0
Abstract: ObjectivesAim of this study was to elucidate an alteration of quality of life (QOL) score before and after video-assisted thoracoscopic surgery (VATS) for non-small cell lung cancer (NSCLC) patients using the 5-level EuroQol-5D questionnaire (EQ-5D-5L).… read more here.
Keywords: surgery; nsclc patients; lung cancer; qol ... See more keywords
The value of different 18F-FDG PET/CT baseline parameters in risk stratification of stage I surgical NSCLC patients
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Nuclear Medicine"
DOI: 10.1007/s12149-018-1301-9
Abstract: ObjectiveAdministration of postoperative chemotherapy to patients with completely resected stage I NSCLC is still a matter of debate. The aim of the present study was to evaluate the value of different baseline 18F-FDG PET parameters… read more here.
Keywords: recurrence; nsclc patients; value; baseline ... See more keywords
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Sign Up to like & getrecommendations! Published in 2018 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2017.12.015
Abstract: IMPORTANCE The identification of anaplastic lymphoma kinase (ALK) rearrangements in 2-5% of non-small cell lung cancer (NSCLC) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (TKI). Crizotinib was the first… read more here.
Keywords: medicine; alk; nsclc patients; treatment ... See more keywords
Feasibility of the administration of chemotherapy using cisplatin plus etoposide for non-small cell lung cancer patients with interstitial lung disease on chest computed tomography
Sign Up to like & getrecommendations! Published in 2017 at "Cancer treatment and research"
DOI: 10.1016/j.ctarc.2016.08.011
Abstract: Abstract Background Chemotherapy for non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) has been challenging due to the possibility of the acute exacerbation of ILD as a life-threatening adverse effect. No acceptable… read more here.
Keywords: nsclc patients; lung cancer; cell lung; non small ... See more keywords
The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Genes and Diseases"
DOI: 10.1016/j.gendis.2020.04.001
Abstract: Abstract TP53 mutations was reported to be correlated to the efficacy of program death-1 (PD-1) and program death ligand-1 (PD-L1). The role of co-mutations of TP53 with other recurrently mutated genes in outcome of anti-PD-(L)1… read more here.
Keywords: mutation 240; tp53 mutation; nsclc patients; longer pfs ... See more keywords
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.04.020
Abstract: BACKGROUND MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive from known driver mutations. Activation of the MEK1-cascade is considered pivotal in resistance to targeted therapy approaches, and… read more here.
Keywords: map2k1 mutations; nsclc patients; cell; lung cancer ... See more keywords